“Inhibiting DGKi seems to reverse the effects of cystic fibrosis”
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a promising potential drug target for cystic fibrosis. Their work, published online today in Cell, also uncovers a large set of genes not previously linked to the disease, demonstrating how a new screening technique can help identify new drug targets.
Cystic fibrosis is a hereditary disease caused by mutations in a single gene called CFTR. These mutations cause problems in various organs, most notably making the lining of the lungs secrete unusually thick mucus. This leads to recurrent life-threatening lung infections, which make it increasingly hard for patients to breathe. The disease is estimated to affect 1 in every 2500-6000 newborns in Europe.
In patients with cystic fibrosis, the mutations to CFTR render it unable to carry out its normal tasks. Among other things, this means CFTR loses the ability to control a protein called the epithelial sodium channel (ENaC). Released from CFTR’s control, ENaC becomes hyperactive, cells in the lungs absorb too much sodium and – as water follows the sodium – the mucus in patients’ airways becomes thicker and the lining of the lungs becomes dehydrated. The only drug currently available that directly counteracts a cystic fibrosis-related mutation only works on the three percent of patients that carry one specific mutation out of the almost 2000 CFTR mutations scientists have found so far.
Thus, if you were looking for a more efficient way to fight cystic fibrosis, finding a therapy that would act upon ENaC instead of trying to correct that multitude of CFTR mutations would seem like a good option. But unfortunately, the drugs that inhibit ENaC, mostly developed to treat hypertension, don’t transfer well to cystic fibrosis, where their effects don’t last very long. So scientists at EMBL, Regensburg University and University of Lisboa set out to find alternatives.
“In our screen, we attempted to mimic a drug treatment,” says Rainer Pepperkok, whose team at EMBL developed the technique, “we’d knock down a gene and see if ENaC became inhibited.”
Starting with a list of around 7000 genes, the scientists systematically silenced each one, using a combination of genetics and automated microscopy, and analysed how this affected ENaC. They found over 700 genes which, when inhibited, brought down ENaC activity, including a number of genes no-one knew were involved in the process. Among their findings was a gene called DGKi. When they tested chemicals that inhibit DGKi in lung cells from cystic fibrosis patients, the scientists discovered that it appears to be a very promising drug target.
“Inhibiting DGKi seems to reverse the effects of cystic fibrosis, but not block ENaC completely,” says Margarida Amaral from the University of Lisboa, “indeed, inhibiting DGKi reduces ENaC activity enough for cells to go back to normal, but not so much that they cause other problems, like pulmonary oedema.”
The Latest on: Cystic fibrosis
- Maryland Chapter Of Cystic Fibrosis Foundation To Have 8th Annual Passion For Food & Wine Eventon September 9, 2019 at 6:43 am
Chef Jay Rohlfing from Cunningham's talks about the event, a personal cooking experience that raises money for the cystic fibrosis foundation.
- Global Cystic Fibrosis(Mucoviscoidosis)Testing Market to Exhibit Significant Opportunity Assessment During the Forecast Period 2019-2029on September 9, 2019 at 1:38 am
Sep 09, 2019 (WiredRelease via COMTEX) -- The key contributing factors of cystic fibrosis(mucoviscoidosis)testing market are fast increasing Sales Strategy, Revenue Generation, Valuable Growth ...
- Softball tournament helps raise money for Cystic Fibrosis in memory of Boise man who died from iton September 7, 2019 at 5:22 pm
Several years ago, a 24-year-old Boise man passed away after losing his battle with Cystic Fibrosis but for the second year in a row, a softball tournament was held in his memory. The tournament also ...
- Researchers explore how talk therapy can help cystic fibrosis patients with mental health problemson September 7, 2019 at 11:59 am
Drexel University researchers are exploring how Acceptance and Commitment Therapy (ACT), a type of talk therapy, delivered via telemedicine, may alleviate the anxiety and depression common among ...
- Firm must come clean on cystic fibrosis wonder drug, says ministeron September 7, 2019 at 8:45 am
Vertex has stalled over a £108million-a-year NHS offer for its lifesaving medicines such as Orkambi for almost 18 months. The National Institute of Health and Care Excellence (NICE) refused to ...
- A brother's inspirational effort to find cystic fibrosis cureon September 4, 2019 at 7:38 pm
Playing 80 minutes of NRL requires endurance but it pales in comparison to what Sean Clarence will achieve with his inspirational #Neverrest campaign. To raise awareness and funds for cystic fibrosis ...
- Wines That Give Back: Tarpon Cellars Supports the Cystic Fibrosis Foundationon September 4, 2019 at 8:38 am
Portion of Every Bottle Sold is Donated to Help Fund Research and Drug Development NAPA, Calif., Sept. 4, 2019 /PRNewswire/ -- Tarpon Cellars, a Napa-based wine label focused on bringing people ...
- Cystic Fibrosis Drugs Market Application, Manufacturer, Sales, Segmentation and Forecast 2019 to 2026on September 3, 2019 at 6:04 am
Sep 03, 2019 (Global QYResearch via COMTEX) -- The global Cystic Fibrosis Drugs market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the ...
- Prenatal genetic testing for cystic fibrosis: a systematic review of clinical effectiveness and an ethics reviewon September 1, 2019 at 10:01 pm
We aimed to assess the clinical value of prenatal testing for cystic fibrosis (CF) and whether ethical considerations would affect endpoint selection. To determine effectiveness, we conducted a ...
- Sisters battling cystic fibrosis told only one can have drug to fight iton September 1, 2019 at 9:13 am
Sisters Kirsty, 29, and Shona, 24, are both fighting cystic fibrosis, but only one sibling has been offered expensive treatment by manufacturer Vertex (Picture: cascadenews.co.uk) Two sisters ...
via Google News and Bing News